

Accepted Manuscript


Outside in: The matrix as a modifier of muscular dystrophy

Mattia Quattrocelli, Melissa J. Spencer, Elizabeth M. McNally

PII: S0167-4889(16)30345-7
DOI: doi:[10.1016/j.bbamcr.2016.12.020](https://doi.org/10.1016/j.bbamcr.2016.12.020)
Reference: BBAMCR 18021

To appear in: *BBA - Molecular Cell Research*

Received date: 17 October 2016
Revised date: 14 December 2016
Accepted date: 19 December 2016



Please cite this article as: Mattia Quattrocelli, Melissa J. Spencer, Elizabeth M. McNally, Outside in: The matrix as a modifier of muscular dystrophy, *BBA - Molecular Cell Research* (2016), doi:[10.1016/j.bbamcr.2016.12.020](https://doi.org/10.1016/j.bbamcr.2016.12.020)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Outside in: the matrix as a modifier of muscular dystrophy

Authors: Mattia Quattrocchi¹, Melissa J. Spencer², Elizabeth M. McNally^{1,†}

Affiliations: ¹Center for Genetic Medicine, Northwestern University, Chicago, IL, USA
²Dept of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

†To whom correspondence should be addressed:

Elizabeth McNally MD PhD
Center for Genetic Medicine
Northwestern University
303 E Superior Lurie 7-123
Chicago, IL 60611
T: 1 312 503 6258 F: 1 312 503 5600
elizabeth.mcnally@northwestern.edu

Running title: Extracellular genetic modifiers for muscular dystrophy

Keywords: Duchenne muscular dystrophy, genetic modifiers, SPP1, osteopontin, LTBP4, Jagged1, TGF β , Notch, myostatin, novel drugs, investigational medicinal products, monoclonal antibodies.

Word count: 4224 (excluding references and figure legends).

Supported by NIH AR052646 (Wellstone Center for Muscular Dystrophy Research), NIH HL61322, NIH NS027072 and the Parent Project Muscular Dystrophy Foundation.

Conflicts of Interest: EMM has provided consulting services for Novartis, Invitae, Mitobridge, Summitplc, AstraZeneca, and Pfizer and served as a data safety monitor for Eli Lilly and Fibrogen, and has patent application 13/957,100 "Mitigating tissue damage and fibrosis via latent TGF β protein (LTBP4).

Download English Version:

<https://daneshyari.com/en/article/5508749>

Download Persian Version:

<https://daneshyari.com/article/5508749>

[Daneshyari.com](https://daneshyari.com)